NASDAQ · Biotechnology

ARCT (ARCT) Stock

$16.74 +3.17% NASDAQ: ARCT Healthcare

Valuation

MetricValue
Price$16.74
Market Cap$475.80M
P/E Ratio-2.93
P/B Ratio0.93
P/S Ratio4.41
EPS (TTM)$0.00
52-Week High$24.17
52-Week Low$5.53
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-30.84%
ROA-24.35%
ROCE-35.05%
Gross Margin-111.94%
Operating Margin-111.94%
Net Margin-1.73%
Debt/Equity0.10
Current Ratio6.69

Annual Financials (USD)

Metric20212022202320242025
Revenue$12.0M$206.0M$158.0M$138.0M$67.0M
Operating Profit$-203.0M$12.0M$-78.0M$-96.0M$-75.0M
Net Profit$-204.0M$9.0M$-30.0M$-81.0M$-66.0M
EPS$-7.74$0.35$-1.12$-3.00$-2.40
Op Margin-1641.3%5.9%-49.6%-69.1%-111.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$393.0M$450.0M$429.0M$344.0M$271.0M
Total Liabilities$165.0M$180.0M$151.0M$103.0M$57.0M
Cash$370.0M$392.0M$292.0M$237.0M$231.0M
Borrowings$69.0M$95.0M$30.0M$29.0M$25.0M

Latest News

Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? Zacks · Jul 3, 2026 Arcturus Therapeutics, Thermo Fisher Scientific to Collaborate on Advancing ARCT-032 in Cystic Fibrosis MT Newswires · Jul 2, 2026 Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis Business Wire · Jul 2, 2026 Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies MarketBeat · Jun 5, 2026 Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary Moby · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-135.0M$32.0M$-18.0M$-60.0M$-74.0M
Investing Cash Flow$-7.0M$-15.0M$-6.0M$-1.0M$0
Financing Cash Flow$1.0M$2.0M$3.0M$5.0M$0
Net Cash Flow$-90.0M$21.0M$-45.0M$-55.0M$-61.0M
Free Cash Flow$-138.0M$24.0M$-21.0M$-60.0M$-74.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-29.47%
Quick Ratio6.31
Interest Coverage—
Return 1Y-52.14%
Return 3Y-82.03%
Return 5Y-77.27%

Ownership

Insiders Held7.99%
Institutions Held80.45%
Institutions Float Held87.43%
Institutional HolderSharesReport Date
Federated Hermes, Inc.3,303,6402026-03-31
ARK Investment Management, LLC2,769,5182026-03-31
Blackrock Inc.2,613,2812026-03-31
Sumitomo Mitsui Trust Group, Inc.2,288,9352026-03-31
Amova Asset Management Americas Inc2,288,9352026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACHV $8.48 +2.79% -5.47 $870.55M 0.00%
AVIR $5.70 +3.83% -2.13 $456.15M 0.00%
FHTX $5.17 -9.14% -6.76 $303.55M 0.00%
HUMA $0.60 +4.59% -4.19 $100.23M 0.00%
IMRX $5.02 +3.61% -3.94 $182.24M 0.00%

About ARCT

ARCT is led by CEO Joseph E. Payne, employs 174 people, headquartered in US, publicly traded since 2013.

ARCT stock trades at $16.74 with a market capitalization of $475.80M. The stock is valued at a price-to-earnings (P/E) ratio of -2.93, price-to-book of 0.93, price-to-sales of 4.41. Over the past 52 weeks the stock has ranged between $5.53 and $24.17, and currently trades 30.7% below its 52-week high.

On profitability, ARCT generates a return on equity (ROE) of -30.84%, return on capital employed of -35.05%, an operating margin of -111.94%, a net profit margin of -1.73%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1160.06 +0.01% JNJ Drug Manufacturers - General $275.21 +1.48% ABBV Drug Manufacturers - General $261.70 +0.66% MRK Drug Manufacturers - General $151.64 +1.19% UNH Medical - Healthcare Plans $399.66 +0.85% NVS Drug Manufacturers - General $162.46 +0.75% AZN Drug Manufacturers - General $161.63 -0.52% AMGN Drug Manufacturers - General $442.84 +1.08% TMO Medical - Diagnostics & Research $608.54 +1.34% NVO Biotechnology $46.77 +3.66% ABT Medical - Devices $110.49 +1.43% GILD Drug Manufacturers - General $149.61 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides